Abstract
The aim of this multicenter study was to compare trazodone (TRA) with two reference drugs, amitriptyline (AMI) and mianserin (MIA), under double-blind conditions, in an elderly population, to ascertain age-related patterns for efficacy and tolerability. One hundred six elderly depressed inpatients, ranging in age from 60 to 83 years, diagnosed as having major depression according to DMS-III, were treated with 75 mg AMI (37 patients), 60 mg MIA (33 patients) or 150 mg TRA (36 patients) p.o. t.i.d. for 5 weeks. There were no differences in the clinical outcome among the three groups of patients at the end of the trial, with a significant amelioration (p <0.01) for the Hamilton Rating Scale for Depression (HRS-D) and the Geriatric Depression Scale (GDS). TRA showed a lower overall prevalence of side effects than AMI or MIA, particularly for anticholinergic (p = 0.03 vs. AMI) and cardiovascular (p = 0.05 vs. MIA) effects. For these data GDS seems to be most reliable in detecting changes in elderly depressive symptomatology; moreover a comparable therapeutic response (among the three drugs) but a better tolerance for atypical antidepressants, particularly TRA, make advisable the use of the latter drug in the elderly population.
| Original language | English |
|---|---|
| Journal | Clinical Neuropharmacology |
| Volume | 12 |
| Issue number | SUPPL. 1 |
| Publication status | Published - 1989 |
Fingerprint
ASJC Scopus subject areas
- Clinical Neurology
- Pharmacology (medical)
- Neuroscience(all)
- Pharmacology, Toxicology and Pharmaceutics(all)
Cite this
Clinical activity and tolerability of trazodone, mianserin, and amitriptyline in elderly subjects with major depression : A controlled multicenter trial. / Altamura, A. C.; Mauri, M. C.; Rudas, N.; Carpiniello, B.; Montanini, R.; Perini, M.; Scapicchio, P. L.; Hadjchristos, C.; Carucci, G.; Minervini, M.; D'Aloise, A.; Malinconico, A.; Aguglia, E.; De Vanna, R.; D'Aronco, R.
In: Clinical Neuropharmacology, Vol. 12, No. SUPPL. 1, 1989.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Clinical activity and tolerability of trazodone, mianserin, and amitriptyline in elderly subjects with major depression
T2 - A controlled multicenter trial
AU - Altamura, A. C.
AU - Mauri, M. C.
AU - Rudas, N.
AU - Carpiniello, B.
AU - Montanini, R.
AU - Perini, M.
AU - Scapicchio, P. L.
AU - Hadjchristos, C.
AU - Carucci, G.
AU - Minervini, M.
AU - D'Aloise, A.
AU - Malinconico, A.
AU - Aguglia, E.
AU - De Vanna, R.
AU - D'Aronco, R.
PY - 1989
Y1 - 1989
N2 - The aim of this multicenter study was to compare trazodone (TRA) with two reference drugs, amitriptyline (AMI) and mianserin (MIA), under double-blind conditions, in an elderly population, to ascertain age-related patterns for efficacy and tolerability. One hundred six elderly depressed inpatients, ranging in age from 60 to 83 years, diagnosed as having major depression according to DMS-III, were treated with 75 mg AMI (37 patients), 60 mg MIA (33 patients) or 150 mg TRA (36 patients) p.o. t.i.d. for 5 weeks. There were no differences in the clinical outcome among the three groups of patients at the end of the trial, with a significant amelioration (p <0.01) for the Hamilton Rating Scale for Depression (HRS-D) and the Geriatric Depression Scale (GDS). TRA showed a lower overall prevalence of side effects than AMI or MIA, particularly for anticholinergic (p = 0.03 vs. AMI) and cardiovascular (p = 0.05 vs. MIA) effects. For these data GDS seems to be most reliable in detecting changes in elderly depressive symptomatology; moreover a comparable therapeutic response (among the three drugs) but a better tolerance for atypical antidepressants, particularly TRA, make advisable the use of the latter drug in the elderly population.
AB - The aim of this multicenter study was to compare trazodone (TRA) with two reference drugs, amitriptyline (AMI) and mianserin (MIA), under double-blind conditions, in an elderly population, to ascertain age-related patterns for efficacy and tolerability. One hundred six elderly depressed inpatients, ranging in age from 60 to 83 years, diagnosed as having major depression according to DMS-III, were treated with 75 mg AMI (37 patients), 60 mg MIA (33 patients) or 150 mg TRA (36 patients) p.o. t.i.d. for 5 weeks. There were no differences in the clinical outcome among the three groups of patients at the end of the trial, with a significant amelioration (p <0.01) for the Hamilton Rating Scale for Depression (HRS-D) and the Geriatric Depression Scale (GDS). TRA showed a lower overall prevalence of side effects than AMI or MIA, particularly for anticholinergic (p = 0.03 vs. AMI) and cardiovascular (p = 0.05 vs. MIA) effects. For these data GDS seems to be most reliable in detecting changes in elderly depressive symptomatology; moreover a comparable therapeutic response (among the three drugs) but a better tolerance for atypical antidepressants, particularly TRA, make advisable the use of the latter drug in the elderly population.
UR - http://www.scopus.com/inward/record.url?scp=0024314681&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0024314681&partnerID=8YFLogxK
M3 - Article
C2 - 2663151
AN - SCOPUS:0024314681
VL - 12
JO - Clinical Neuropharmacology
JF - Clinical Neuropharmacology
SN - 0362-5664
IS - SUPPL. 1
ER -